Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6Other neoplasm 1

Conditions

Skin Diseases 1Precancerous Conditions 1Keratosis, Actinic 1Keratosis 1

Interventions

Biopsy 8Polymerase Chain Reaction 6Peripheral Blood Stem Cell Transplantation 5Epoetin Alfa 5Surveys and Questionnaires 4Sulindac 4Microarray Analysis 4Gene Expression Profiling 4Early Intervention, Educational 4Cyclophosphamide 4Colposcopy 4Cisplatin 4Cetuximab 4Celecoxib 4fludarabine phosphate 3Vaginal Smears 3Selenium 3Pemetrexed 3Methotrexate 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Eflornithine 3Darbepoetin alfa 3Aspirin 3Antilymphocyte Serum 3Whole-Body Irradiation 2Vitamin E 2Videotape Recording 2Tacrolimus 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × BF-200 ALA × Other neoplasm × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡